Movatterモバイル変換


[0]ホーム

URL:


MXPA00002933A - Method for preventing the misuse of a transdermal therapeutic system - Google Patents

Method for preventing the misuse of a transdermal therapeutic system

Info

Publication number
MXPA00002933A
MXPA00002933AMXPA/A/2000/002933AMXPA00002933AMXPA00002933AMX PA00002933 AMXPA00002933 AMX PA00002933AMX PA00002933 AMXPA00002933 AMX PA00002933AMX PA00002933 AMXPA00002933 AMX PA00002933A
Authority
MX
Mexico
Prior art keywords
layer
substance
process according
substances
tts
Prior art date
Application number
MXPA/A/2000/002933A
Other languages
Spanish (es)
Inventor
Becher Frank
Annkatrin Klink
Original Assignee
Lts Lohmann Therapiesysteme Gmbh 56567 Neuwied De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapiesysteme Gmbh 56567 Neuwied DefiledCriticalLts Lohmann Therapiesysteme Gmbh 56567 Neuwied De
Publication of MXPA00002933ApublicationCriticalpatent/MXPA00002933A/en

Links

Abstract

According to the invention, denaturing agents are added to a transdermal therapeutic system to prevent misuse in the form of unauthorised oral application.

Description

METHOD TO PROTECT A PERSON FROM THEPOLLUTION AS A RESULT OF AN APPLICATIONORAL MISTAKE OF TOXIC SUBSTANCES OF A SYSTEMTHERAPEUTIC PERCUTANEOUS, AS WELL AS SYSTEMSPERCUTANEOUS THERAPEUTICS WITH A DENATURALIZINGField of the InventionThe invention relates to a method for the protection of a person against contamination as a result of the undue oral application of toxic substances of a percutaneous therapeutic system (TTS), comprising at least one layer containing active ingredient, in particular with a self-adhesive liner, as well as at least one subsequent layer impermeable to the active principle, as well as a TTS with a denaturant.
Background of the InventionIn a series of TTS there is a serious risk that unwanted effects may occur in theIf people can have oral contact with an active ingredient that can be separated from the system - be it new systems orRef: 32947 systems that have been removed. For example, young children often put all the objects that get their attention in the mouth and at least suck or chew them. In particular, this can not be avoided when children have casual access to systems of this type, in particular without protective release liner. To date, there have been no known incidents of this type, but the health authorities are increasingly afraid of this and for this reason they demand that these containers be safe to avoid unforeseen openings. In fact, containers of this type have been developed in various forms. However, they do not prevent a child from putting a TTS in his mouth once the container is opened or if a used patch reaches his hands in some way. Particularly in the case of TTS with active ingredients such as anesthetics, analgesics, tranquillizers or ps i co-drugs, undue oral intake can be harmful to health. On the other hand, drug addicts may be tempted to extract these active ingredients from the percutaneous therapeutic systems by sucking or chewing them.
The denaturing process is already known, to which the ethyl alcohol suitable for consumption is subjected, to be released on the market in the form of alcohol to be burned. On the other hand, no case of denaturation of active pharmaceutical ingredients is known to date.
Description of the invention.
The aim of the present invention is to offer a method for the protection of a person, of the type mentioned in the generic term of claim 1, so that the aforementioned oral abuse is not possible, although it is otherwise avoided a disadvantageous alteration of the active therapeutic principle in the system and also preventing any damage to health as a consequence of an undue oral application.
To solve this problem, it is proposed with the method according to the invention, to add a therapeutically neutral and non-interacting substance with unpleasant taste.
Because this substance offers a highly unpleasant and unexpected taste, a first oral contact with the TTS according to the invention or with one of its denatured layers will suffice for a spontaneous reaction to force the immediate spitting of the patch in question, avoiding in this way, children or drug addicts orally use the active substance contained in the patch in an improper way.
One configuration foresees that, for the denaturing of a TTS, a substance is used that produces the urge to vomit and consequently prevents the person in question from being tempted to proceed to an oral application.
Another configuration of the method according to the invention provides that the substance is applied on the layer containing active ingredient in a separate, extremely thin layer and does not prevent the permeation of the active principle. This has the advantage that at the first contact of the buccal mucosa or tongue with the TTS, before the contamination with the active ingredient-containing layer occurs, the extremely unpleasant taste prevents a later oral contact.
It is also possible for the substance to be applied additionally on the back layer in a separate layer, preferably very thin. In this way, the denaturing effect is further intensified.
It is provided that the separated layer of the substance is applied in a thickness comprised between 10 and 100 μm, preferably between 5 and 20 μm.
A particularly preferred configuration of the invention also provides for the use of a substance that causes irritation, such as burning of the mucous membranes of the oral cavity and the tongue. A single negative experience should suffice to prevent, permanently, the child or drug addict from continuing to be tempted to enter into oral contact with a TTS. In addition, a similar effect can be achieved by using a substance that causes a very bitter and permanent taste.
An effective configuration of the method according to the invention provides that for the denaturing of at least one layer of a TTS it is used as a bitter substance or substance of unpleasant taste: gallic acid, quinine, tannin, narrowness, caffeine (pure), lobeline, essence of tea, certain crops of mold fungi, denatured or curdled substances, turpentine or ammonia.
To achieve an embodiment of the method, it has been foreseen that. the substances used for the denaturation are introduced into a coating layer, with which the active ingredient-containing layer is coated and, if necessary, the subsequent layer. The best solution is to use a coating of soluble coating in contact with saliva.
The method is non-complicated and effective and protects children and / or drug addicts from any undue oral use of toxic substances contained in a percutaneous therapeutic system. In this way, the method and the TTS according to the invention optimally solve the problem raised at the beginning. It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Having described the invention as above, the content of the following is claimed as property.

Claims (12)

Claims
1. A process to protect a person from contamination, as a consequence of the undue oral application of toxic substances contained in a percutaneous therapeutic system (TTS), comprising at least one layer containing active substance, in particular with self-adhesive coating, as well as at least one other subsequent layer impermeable to the active principle, characterized in that a therapeutically neutral and non-interacting substance with an unpleasant taste is added.
2. The process according to claim 1, characterized in that the unpleasant taste substance is added to at least the active ingredient containing layer.
3. The process according to claim 1 or 2, characterized in that the substances used for the denaturation are introduced into a coating layer with which the active ingredient-containing layer and, where appropriate, the back layer is coated.
4. The process according to claim 3, characterized in that a coating layer is used, which dissolves in contact with the saliva.
5. The process according to one or more of claims 1 to A, characterized in that a substance that makes you want to vomit is used.
6. The process according to one or more of the rei indications 1 to 5, characterized in that the substance is applied on the layer containing the active ingredient in a separate, very thin layer and does not prevent the permeation of the active principle.
7. The process according to one or more of claims 1 to 6, characterized in that the substance is also applied on the back layer in a very thin, separate layer.
8. The process according to one or more of claims 1 to 7, characterized in that the separated layer of the substance is applied in a thickness comprised between 10 and 100 μm and preferably between 5 and 20 μm.
9. The process according to one or more of claims 1 to 8, characterized in that a substance is used that produces an irritation, such as burning of the mucous membranes of the oral cavity and the tongue.
10. The process according to one or more of claims 1 to 9, characterized in that a substance which produces an intense bitter taste and in particular leaves a bad taste in the mouth is used.
11. The process according to one or more of claims 1 to 10, characterized in that for the denaturing of at least one layer of a TTS it is used as bitter substances or substances of unpleasant taste: gallic acid, quinine, tannin, narrowness, caffeine (pure ), lobeline, tea essence, cultivation of mold fungi, denatured or curdled substances, turpentine or ammonia.
12. A TTS, characterized in that it comprises at least one active ingredient-containing layer, in particular with self-adhesive coating, as well as at least one other subsequent layer impermeable to the active principle, which contains a denaturant. METHOD OF PROTECTING A PERSON FROM POLLUTION AS A RESULT OF AN UNDUE ORAL APPLICATION OF TOXIC SUBSTANCES OF A SYSTEM PERCUTANEOUS THERAPEUTIC, AS WELL AS PERCUTANEOUS THERAPEUTIC SYSTEMS WITH A DENATURALIZER Summary of the Invention. The invention is to avoid an undue oral application by adding denaturants to a percutaneous therapeutic system.
MXPA/A/2000/002933A1997-10-012000-03-24Method for preventing the misuse of a transdermal therapeutic systemMXPA00002933A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
DE19743484.31997-10-01

Publications (1)

Publication NumberPublication Date
MXPA00002933Atrue MXPA00002933A (en)2002-05-09

Family

ID=

Similar Documents

PublicationPublication DateTitle
US7011843B2 (en)Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
CA2169729C (en)Water-soluble pressure-sensitive mucoadhesive
RU2351315C2 (en)Films, dissolving in mouth cavity
US8784872B2 (en)Formulation for decreasing tobacco, alcohol, drug or food consumption
EP2765989B1 (en)Methods and compositions for rapid transbuccal delivery of active agents
WO2008025791A1 (en)Buprenophine-wafer for drug substitution therapy
NO952906L (en) Pharmaceutical formulation for the treatment of nicotine addiction
US20030153590A1 (en)Method of treating alcoholism or alcohol abuse
US20100256197A1 (en)Nicotine Dissolving Film With Or Without Menthol
JP2009035561A (en)Method for preventing misuse of transdermal therapeutic system
MXPA00002933A (en)Method for preventing the misuse of a transdermal therapeutic system
US20070155774A1 (en)Oral formulations of desoxypeganine and thereof uses
HK1029919B (en)Method for preventing the misuse of a transdermal therapeutic system
US20140271847A1 (en)Formulations and methods for rapid penile erections
CZ20001025A3 (en) A method of preventing abuse of a transdermal therapeutic system
EP2258354B1 (en)Compounds and methods for controlling alcohol intake
JP2001199880A (en) Sickness prevention agent
HissThesaurus of Proprietary Preparations and Pharmaceutical Specialties: Including" patent" Medicines, Proprietary Pharmaceuticals, Open-formula Specialties, Synthetic Remedies, Etc
PfisterOral transmucosal delivery of nicotine: smoking cessation therapy
WhittakerNicotine replacement therapy: medicine cupboard
HK1201203B (en)Methods and compositions for rapid transbuccal delivery of active agents

[8]ページ先頭

©2009-2025 Movatter.jp